First-in-human phase Ib study of ATRC-101, an engineered version of a patient-derived antibody targeting a tumor-restricted ribonucleoprotein complex. Benjamin, J., Higgins, N., Millward, C., Defalco, J., Manning-Bog, A., Aydin, I. T., Zhang, D., Lippow, S., Scholz, A., Leung, Y., Zhu, Y., Sedello, A., Rogers, Z., Dhawan, I., Emerling, D., Robinson, W. H., Serafini, T., Greenberg, N. LIPPINCOTT WILLIAMS & WILKINS. 2020

View details for Web of Science ID 000560368309083